Collegium Pharmaceutical (COLL) Short term Debt (2016 - 2026)
Collegium Pharmaceutical has reported Short term Debt over the past 11 years, most recently at $17.6 million for Q4 2025.
- For Q4 2025, Short term Debt fell 39.34% year-over-year to $17.6 million; the TTM value through Dec 2025 reached $17.6 million, down 39.34%, while the annual FY2025 figure was $17.6 million, 39.34% down from the prior year.
- Short term Debt for Q4 2025 was $17.6 million at Collegium Pharmaceutical, down from $64.6 million in the prior quarter.
- Over five years, Short term Debt peaked at $183.3 million in Q1 2023 and troughed at $17.6 million in Q4 2025.
- A 5-year average of $106.1 million and a median of $82.3 million in 2022 define the central range for Short term Debt.
- Biggest five-year swings in Short term Debt: surged 236.07% in 2022 and later crashed 84.21% in 2024.
- Year by year, Short term Debt stood at $48.4 million in 2021, then surged by 236.07% to $162.5 million in 2022, then grew by 12.82% to $183.3 million in 2023, then crashed by 84.21% to $29.0 million in 2024, then tumbled by 39.34% to $17.6 million in 2025.
- Business Quant data shows Short term Debt for COLL at $17.6 million in Q4 2025, $64.6 million in Q3 2025, and $64.6 million in Q2 2025.